HOME >> MEDICINE >> NEWS
Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Philadelphia, PA., May 19, 2003 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that a landmark analysis of studies comparing antidepressant treatments demonstrated that significantly more patients achieved remission (virtual elimination) of their depression symptoms, and resolution of both emotional and physical symptoms, when treated with EFFEXOR/EFFEXOR XR (venlafaxine HCl) than with commonly used selective serotonin reuptake inhibitors (SSRIs) or placebo. The analysis was presented in two poster presentations at the American Psychiatric Association's (APA) annual meeting in San Francisco.

The analysis compared EFFEXOR®/EFFEXOR XR to the SSRIs PAXIL® (paroxetine), PROZAC® (fluoxetine), ZOLOFT® (sertraline), LUVOX® (fluvoxamine), and CELEXA (citalopram) and comprised the entire worldwide dataset of Wyeth-sponsored registration and post-marketing, published and unpublished, SSRI-controlled clinical studies of EFFEXOR/EFFEXOR XR to date.

"Given the urgency to treat a patient to remission, these data reinforce EFFEXOR XR as a first-line therapy for depression," says Dr. Eric Hollander, Professor of Psychiatry and Director of Psychopharmacology at Mount Sinai School of Medicine in New York City. "This is important information for physicians as remission is a critical milestone in preventing symptom recurrence and depression relapse."

In one poster it was determined that EFFEXOR/EFFEXOR XR-treated patients had significantly higher remission rates than those treated with the studied SSRIs using standard evaluations including scoring seven or less on the 17-item Hamilton Rating Scale for Depression (HAM-D17) and less than 10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Specifically, the HAM-D17 evaluation revealed a 41 percent remission rate for EFFEXOR/EFFEXOR XR patients, significantly greater than that of patients receiving an SSRI (35 percent, p<0.001), or a placebo (25 percent,
'"/>

Contact: Douglas Petkus, Wyeth Pharmaceuticals
484-865-5140
Porter Novelli
19-May-2003


Page: 1 2 3 4

Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
3. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
4. Landmark study demonstrates potential for nerve regeneration treatment of stroke
5. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
6. Landmark study uncovers reasons behind recurring back injury
7. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
8. Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis
9. Landmark school-based social influences smoking-prevention program found not to work
10. U.S., British scientific societies honor penicillin as International Chemical Landmark
11. CODE-2*: Landmark study on the costs of type 2 diabetes in Europe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/14/2019)... ... ... Reset Summer Camp, one of the only summer camp programs specifically designed for ... application portal for summer 2019. In addition, the camp has appointed top parenting ... popularly known as Dr. G – to oversee family engagement. , “We’re excited to ...
(Date:3/14/2019)... (PRWEB) , ... March 14, 2019 , ... Cell & ... Approval, **An FDAnews Webinar**, Thursday, March 28, 2019, 1:30 p.m. - 3:00 p.m. EDT, ... 10 to 20 cell and gene therapy products a year. , That will ...
(Date:3/12/2019)... ... March 12, 2019 , ... ... events, AdventHealth care teams will provide comprehensive, on-site services at the exclusive Midway ... by Advanced Auto Parts. The Infield Care Center will be staffed with emergency ...
(Date:3/12/2019)... BEACH, Calif. (PRWEB) , ... March 12, 2019 ... ... , today announced the availability of HIPAA training for healthcare organizations and their ... to comply with HIPAA regulations and keep patients’ personal and health information private ...
(Date:3/12/2019)... ... 2019 , ... When it comes to selecting a physician ... pain and diseases of joints, muscles, tendons and ligaments, “choose wisely,” says noted ... Indiana Jones. , “Some clinics and health centers have been built on the ...
Breaking Medicine News(10 mins):
(Date:3/16/2019)... ... March 16, 2019 , ... Oral surgeons ... to announce that they are launching the JawFixers Implant Synergy Boot Camp. The first ... series is designed for implant clinicians to better understand the placement of and newest ...
(Date:3/15/2019)... ... , ... Peter Saltonstall , president and chief executive officer at the ... Institute’s 18th annual commencement ceremony on May 18, 2019. , NORD, now in ... than 30 years as a senior executive in both for-profit and not-for-profit healthcare environments. ...
(Date:3/14/2019)... , ... March 14, 2019 , ... ... (MBE) LOUi Consulting Group, Inc. (LCGI) its fourth consecutive multi-million-dollar electronic health records ... a $7M, 22-month contract to maintain the computer servers that gather and share ...
Breaking Medicine Technology:
Cached News: